Mechanistically, we uncovered that PARG loss mediates PARPi resistance by partially restoring PARP1 signaling, and we observed that biopsies of TNBC and high serous ovarian carcinoma patients carry a substantial percentage of tumor cells with low expression of PARG and increased PARylation (Gogola et al, 2018). The gene discussed is PARG; the disease is ovarian serous carcinoma.